MABVAX THERAPEUTICS HOLDINGS, INC.

San Diego, CA · Biotech · Private

Fully human antibody discovery platform for cancer therapeutic development

Claim this profile

Follows are private to you and power your alerts

Updated · mabvax.com

Sector
Biotech
Headquarters
San Diego, CA
Latest Form D
$830K, May 2018
Total capital
$25M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$25M
5 Form D · last May 2018
101 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20142015201620172018FEDERAL ↑EQUITY ↓Cumulative $25M1st Form D$4.6M3rd Form D$11.6M4th Form D$2.8M5th Form D$830K
20142015201620172018FEDERAL ↑EQUITY ↓Cumulative $25M3rd Form D$11.6M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$830K
  • Private capital raisedForm D · SEC · 4th filing$2.8M
  • Private capital raisedForm D · SEC · 3rd filing$11.6M
  • Private capital raisedForm D · SEC · 2nd filing$5.2M
  • Private capital raisedForm D · SEC · 1st filing$4.6M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Gregory P. HansonExecutive OfficerNamed in SEC Form D filings
  • J. David HansenExecutive Officer, DirectorNamed in SEC Form D filings
  • Jeffrey F. EisenbergDirectorNamed in SEC Form D filings
  • Jeffrey RavetchDirectorNamed in SEC Form D filings
  • Kenneth CohenDirectorNamed in SEC Form D filings
  • Paul W. MaffuidExecutive OfficerNamed in SEC Form D filings
Show all 12 people
  • Paul V. MaierDirectorNamed in SEC Form D filings
  • Paul W. ResnickExecutive OfficerNamed in SEC Form D filings
  • Philip O. LivingstonDirectorNamed in SEC Form D filings
  • Robert HoffmanDirectorNamed in SEC Form D filings
  • Thomas VarranoDirectorNamed in SEC Form D filings
  • Thomas C. VarvaroDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • STEMETIX, INC.Similar federal contract value in Biotech · null in contracts
  • GlycosBio Inc.Similar federal contract value in Biotech · null in contracts
  • ARONORA INCSimilar federal contract value in Biotech · null in contracts
  • BIOTIME, INC.Similar federal contract value in Biotech · null in contracts
  • HELIUS MEDICAL TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
  • GID BIO, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .